Paris, July 8th, 2024,

One year after the transforming double acquisition of Dessillons & Dutrillaux and Electro Concept Médical, DDA & Company once again advised Spengler Group in the cross-border acquisition of the German manufacturer Luxamed, consolidating its positioning as a European champion in the design and manufacture of medical devices.

Led by a trio of managers who all significantly reinvest in the combined group, Luxamed is one of the European leaders in the niche of lighting technologies dedicated to medical diagnosis, with a range of otoscopes, dermatoscopes, ophthalmoscopes and examination lamps in particular.

Mayeul Caron and Victor Cabaud, Partner and Senior Investment Manager at Andera Partners, state: ” This is the 4th acquisition we have supported in 2 years, 3 of which have been transformative. With Luxamed, we are completing the transformation of a French player in the medical equipment sector into a true European champion in the manufacture of high value-added medical diagnostic equipment, which was our original investment thesis. We are further strengthening the Group’s brands and product offering, its capacity for innovation and control of supply chains in an increasingly demanding context, where healthcare must be safeguarded and growth made as sustainable as possible. The Spengler Group’s decarbonization targets will shortly be approved by the SBTi (science-based target initiative), validating the Group’s contribution to the international effort to limit global warming to below 2°C.”

Joël Malabat, President of Spengler Group, adds: ” Under the founders’ tenure, Luxamed has become a recognized brand in the European market. This combination is first and foremost a human adventure; we have been working on this project for several months with Luxamed’s founders, and we are convinced that it unlocks major industrial and commercial potential in all the markets where we are present. This transaction will enhance the attractiveness of our brand portfolio, amplify the decarbonization of our activities through Made in Europe manufacturing, and strengthen our capacity for innovation, with the aim of helping healthcare professionals to manage their patients.”

Matthias Dubb, Bernhard Winter and Harald Bühler, Founders of Luxamed complete: “We have known the Spengler Group for several years. It has been quite natural to us to come together when we considered how to significantly accelerate our growth. The product synergies are obvious, and our DNAs are similar: leading brand strategy, innovation, ethics and flexibility.”

Alexandre Odin, Partner at DDA & Company, concludes: “The one-on-one discussion framework enabled the Spengler and Luxamed teams to build a solid, carefully thought-out project that is already bearing fruit. This transaction marks Spengler’s access to a leading European status and is a very promising strategic step”.

The DDA & Company team, composed of Alexandre Odin and Florian Charrière, advised Spengler Group in this acquisition operation.